Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.

Eun Kyung Cho, Soo Mee Bang, Jeong Yeal Ahn, Seung Min Yoo, Pil Whan Park, Yieh Hea Seo, Dong Bok Shin, Jae Hoon Lee

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

BACKGROUND: The t (8;21) (q22;q22), which produces the fusion gene AML1/ETO, is associated with relatively good prognosis and, in particular, with a good response to cytosine arabinoside. Analysis of t (8;21) positive leukemic blasts has shown characteristic morphological and immunological features. We performed this study to investigate the incidence of AML1/ETO rearrangement in adult acute myelogenous leukemia (AML), especially in M2 subtype, to make a comparison of clinical, morphological and immunophenotypic characteristics between AML1/ETO rearrangement positive and negative group in patients with AML and to analyze the correlation with other biological parameters. METHODS: From May 1995 to Sept. 2000, fifty-nine patients with AML, including twenty-nine AML-M2, were studied. RNAs were extracted from leukemic cells and reverse transcriptase mediated polymerase chain reaction (RT-PCR) for AML1/ETO fusion transcript was done. Chromosome study, immunophenotypic and clinical characteristics were analyzed and statistical analysis was done. RESULTS: The incidence of AML1/ETO fusion transcripts was 22.0% in AML and 44.8% in AML-M2. The morphologic finding of bone marrow in AML-M2 showed higher incidence of Auer rods, large blast with prominent golgi and abnormal granules in AML1/ETO positive patients. There was no significant difference of immunophenotype. AML patients with AML1/ETO had a tendency of higher complete remission rate (81.8% vs 56.6%, p = 0.13). The overall survival (median; 82.2 weeks vs 34.4 weeks, p = 0.02) and progression free survival (median; 50.9 weeks vs 20.4 weeks, p = 0.02) of AML1/ETO positive group were longer than those of the negative group in AML. AML-M2 patients with AML1/ETO rearrangement had also a tendency of longer overall survival and progression free survival, although there was no significant difference between both groups. CONCLUSION: Our data suggest that AML1/ETO rearrangement is detected frequently in AML, especially M2, and is a favorable prognostic factor. Thus, molecular diagnostic approaches should be used routinely to identify patients with this gentic subtype of AML.

Original languageEnglish
Pages (from-to)13-20
Number of pages8
JournalThe Korean journal of internal medicine
Volume18
Issue number1
StatePublished - 1 Jan 2003

Fingerprint

Acute Myeloid Leukemia
Disease-Free Survival
Incidence
Survival
Molecular Pathology
Gene Fusion
Cytarabine
Reverse Transcriptase Polymerase Chain Reaction
Chromosomes
Bone Marrow
RNA

Cite this

Cho, E. K., Bang, S. M., Ahn, J. Y., Yoo, S. M., Park, P. W., Seo, Y. H., ... Lee, J. H. (2003). Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. The Korean journal of internal medicine, 18(1), 13-20.
Cho, Eun Kyung ; Bang, Soo Mee ; Ahn, Jeong Yeal ; Yoo, Seung Min ; Park, Pil Whan ; Seo, Yieh Hea ; Shin, Dong Bok ; Lee, Jae Hoon. / Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. In: The Korean journal of internal medicine. 2003 ; Vol. 18, No. 1. pp. 13-20.
@article{724b65f08f234ceda30511fff37b6c19,
title = "Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.",
abstract = "BACKGROUND: The t (8;21) (q22;q22), which produces the fusion gene AML1/ETO, is associated with relatively good prognosis and, in particular, with a good response to cytosine arabinoside. Analysis of t (8;21) positive leukemic blasts has shown characteristic morphological and immunological features. We performed this study to investigate the incidence of AML1/ETO rearrangement in adult acute myelogenous leukemia (AML), especially in M2 subtype, to make a comparison of clinical, morphological and immunophenotypic characteristics between AML1/ETO rearrangement positive and negative group in patients with AML and to analyze the correlation with other biological parameters. METHODS: From May 1995 to Sept. 2000, fifty-nine patients with AML, including twenty-nine AML-M2, were studied. RNAs were extracted from leukemic cells and reverse transcriptase mediated polymerase chain reaction (RT-PCR) for AML1/ETO fusion transcript was done. Chromosome study, immunophenotypic and clinical characteristics were analyzed and statistical analysis was done. RESULTS: The incidence of AML1/ETO fusion transcripts was 22.0{\%} in AML and 44.8{\%} in AML-M2. The morphologic finding of bone marrow in AML-M2 showed higher incidence of Auer rods, large blast with prominent golgi and abnormal granules in AML1/ETO positive patients. There was no significant difference of immunophenotype. AML patients with AML1/ETO had a tendency of higher complete remission rate (81.8{\%} vs 56.6{\%}, p = 0.13). The overall survival (median; 82.2 weeks vs 34.4 weeks, p = 0.02) and progression free survival (median; 50.9 weeks vs 20.4 weeks, p = 0.02) of AML1/ETO positive group were longer than those of the negative group in AML. AML-M2 patients with AML1/ETO rearrangement had also a tendency of longer overall survival and progression free survival, although there was no significant difference between both groups. CONCLUSION: Our data suggest that AML1/ETO rearrangement is detected frequently in AML, especially M2, and is a favorable prognostic factor. Thus, molecular diagnostic approaches should be used routinely to identify patients with this gentic subtype of AML.",
author = "Cho, {Eun Kyung} and Bang, {Soo Mee} and Ahn, {Jeong Yeal} and Yoo, {Seung Min} and Park, {Pil Whan} and Seo, {Yieh Hea} and Shin, {Dong Bok} and Lee, {Jae Hoon}",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "18",
pages = "13--20",
journal = "The Korean journal of internal medicine",
issn = "1226-3303",
publisher = "Korean Association of Internal Medicine",
number = "1",

}

Cho, EK, Bang, SM, Ahn, JY, Yoo, SM, Park, PW, Seo, YH, Shin, DB & Lee, JH 2003, 'Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.', The Korean journal of internal medicine, vol. 18, no. 1, pp. 13-20.

Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. / Cho, Eun Kyung; Bang, Soo Mee; Ahn, Jeong Yeal; Yoo, Seung Min; Park, Pil Whan; Seo, Yieh Hea; Shin, Dong Bok; Lee, Jae Hoon.

In: The Korean journal of internal medicine, Vol. 18, No. 1, 01.01.2003, p. 13-20.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia.

AU - Cho, Eun Kyung

AU - Bang, Soo Mee

AU - Ahn, Jeong Yeal

AU - Yoo, Seung Min

AU - Park, Pil Whan

AU - Seo, Yieh Hea

AU - Shin, Dong Bok

AU - Lee, Jae Hoon

PY - 2003/1/1

Y1 - 2003/1/1

N2 - BACKGROUND: The t (8;21) (q22;q22), which produces the fusion gene AML1/ETO, is associated with relatively good prognosis and, in particular, with a good response to cytosine arabinoside. Analysis of t (8;21) positive leukemic blasts has shown characteristic morphological and immunological features. We performed this study to investigate the incidence of AML1/ETO rearrangement in adult acute myelogenous leukemia (AML), especially in M2 subtype, to make a comparison of clinical, morphological and immunophenotypic characteristics between AML1/ETO rearrangement positive and negative group in patients with AML and to analyze the correlation with other biological parameters. METHODS: From May 1995 to Sept. 2000, fifty-nine patients with AML, including twenty-nine AML-M2, were studied. RNAs were extracted from leukemic cells and reverse transcriptase mediated polymerase chain reaction (RT-PCR) for AML1/ETO fusion transcript was done. Chromosome study, immunophenotypic and clinical characteristics were analyzed and statistical analysis was done. RESULTS: The incidence of AML1/ETO fusion transcripts was 22.0% in AML and 44.8% in AML-M2. The morphologic finding of bone marrow in AML-M2 showed higher incidence of Auer rods, large blast with prominent golgi and abnormal granules in AML1/ETO positive patients. There was no significant difference of immunophenotype. AML patients with AML1/ETO had a tendency of higher complete remission rate (81.8% vs 56.6%, p = 0.13). The overall survival (median; 82.2 weeks vs 34.4 weeks, p = 0.02) and progression free survival (median; 50.9 weeks vs 20.4 weeks, p = 0.02) of AML1/ETO positive group were longer than those of the negative group in AML. AML-M2 patients with AML1/ETO rearrangement had also a tendency of longer overall survival and progression free survival, although there was no significant difference between both groups. CONCLUSION: Our data suggest that AML1/ETO rearrangement is detected frequently in AML, especially M2, and is a favorable prognostic factor. Thus, molecular diagnostic approaches should be used routinely to identify patients with this gentic subtype of AML.

AB - BACKGROUND: The t (8;21) (q22;q22), which produces the fusion gene AML1/ETO, is associated with relatively good prognosis and, in particular, with a good response to cytosine arabinoside. Analysis of t (8;21) positive leukemic blasts has shown characteristic morphological and immunological features. We performed this study to investigate the incidence of AML1/ETO rearrangement in adult acute myelogenous leukemia (AML), especially in M2 subtype, to make a comparison of clinical, morphological and immunophenotypic characteristics between AML1/ETO rearrangement positive and negative group in patients with AML and to analyze the correlation with other biological parameters. METHODS: From May 1995 to Sept. 2000, fifty-nine patients with AML, including twenty-nine AML-M2, were studied. RNAs were extracted from leukemic cells and reverse transcriptase mediated polymerase chain reaction (RT-PCR) for AML1/ETO fusion transcript was done. Chromosome study, immunophenotypic and clinical characteristics were analyzed and statistical analysis was done. RESULTS: The incidence of AML1/ETO fusion transcripts was 22.0% in AML and 44.8% in AML-M2. The morphologic finding of bone marrow in AML-M2 showed higher incidence of Auer rods, large blast with prominent golgi and abnormal granules in AML1/ETO positive patients. There was no significant difference of immunophenotype. AML patients with AML1/ETO had a tendency of higher complete remission rate (81.8% vs 56.6%, p = 0.13). The overall survival (median; 82.2 weeks vs 34.4 weeks, p = 0.02) and progression free survival (median; 50.9 weeks vs 20.4 weeks, p = 0.02) of AML1/ETO positive group were longer than those of the negative group in AML. AML-M2 patients with AML1/ETO rearrangement had also a tendency of longer overall survival and progression free survival, although there was no significant difference between both groups. CONCLUSION: Our data suggest that AML1/ETO rearrangement is detected frequently in AML, especially M2, and is a favorable prognostic factor. Thus, molecular diagnostic approaches should be used routinely to identify patients with this gentic subtype of AML.

UR - http://www.scopus.com/inward/record.url?scp=0038314364&partnerID=8YFLogxK

M3 - Article

C2 - 12760263

AN - SCOPUS:0038314364

VL - 18

SP - 13

EP - 20

JO - The Korean journal of internal medicine

JF - The Korean journal of internal medicine

SN - 1226-3303

IS - 1

ER -